Medical Education

Delve into the latest in medical education resources for NASH. Explore new studies, teaching methodologies, and advancements shaping NASH education for healthcare professionals.

Examining the Role of Abnormal Mitochondrial in Fatty Liver Diseases

Authors: Fromenty B, Roden M
Published in Journal of Hepatology (February 2023)
Mitochondria play a pivotal role in numerous features of hepatic function, driving processes such as substrate metabolism, energy production through cellular signalling, and biotransformation of xenobiotics.
Read MoreExamining the Role of Abnormal Mitochondrial in Fatty Liver Diseases

NASH Progression and Clinical Outcomes: Defining Predictive LSM-VCTE Thresholds

Authors: Loomba R, Huang DQ, Sanyal AJ et al.
Published in Gut (March 2023)
In patients with non-alcoholic steatohepatitis (NASH), the risk of liver-related mortality and decompensation is known to increase proportionally with fibrosis stage. Non-invasive tools, including liver stiffness by vibration-controlled transient elastography (LS-VCTE), have been shown to accurately predict fibrosis stage in NASH patients.
Read MoreNASH Progression and Clinical Outcomes: Defining Predictive LSM-VCTE Thresholds

NAFLD: Global and Regional Prevalence, Incidence, and Mortality Rates

Authors: Younossi ZM, Golabi P, Paik JM et al.
Published in Hepatology (April 2023)
Non-alcoholic fatty liver disease (NAFLD) is a major contributor to liver-related illnesses and fatalities worldwide. Its clearly established two-way connection with obesity, a significant public health issue showing increasing prevalence rates globally and regionally, necessitates comprehensive education focused on NAFLD and the implementation of worldwide policies to address it effectively.
Read MoreNAFLD: Global and Regional Prevalence, Incidence, and Mortality Rates

NAFLD and New-Onset Heart Failure: What is the Link?

Authors: Inciardi RM, Mantovani A and Targher G
Published in Current Heart Failure Reports (July 2023)
Non-alcoholic fatty liver disease (NAFLD) and congestive heart failure (HF) represent global public health concerns.
Read MoreNAFLD and New-Onset Heart Failure: What is the Link?

Adipose tissue insulin resistance and fibrosis stage in NASH

Authors: Kalavalapalli S, Leiva EG, Lomonaco R et al.
Published in Journal of Clinical Endocrinology and Metabolism (April 2023)
Understanding the drivers of non-alcoholic fatty liver disease (NAFLD) is crucial to developing pharmacotherapies that effectively target it. Insulin resistance (IR), whose onset precipitates type 2 diabetes (T2D), is known to play a crucial role in the development of hepatic steatosis.
Read MoreAdipose tissue insulin resistance and fibrosis stage in NASH

Hepatic Macrophages in NAFLD: A Novel Therapeutic Target?

Authors: Vonderlin J, Chavakis T, Sieweke M et al.
Published in Cellular and Molecular Gastroenterology and Hepatology (March 2023)
Non-alcoholic fatty liver disease (NAFLD) encompasses a spectrum of pathologies ranging from simple steatosis to steatohepatitis (NASH) and fibrosis.
Read MoreHepatic Macrophages in NAFLD: A Novel Therapeutic Target?

MASLD: A New Fatty Liver Disease Nomenclature?

Authors: Rinella ME, Lazarus JV, Ratziu V et al.
Published in Journal of Hepatology (June 2023)
Disease awareness, patient stratification, diagnosis, and access to care are all helped or hindered by a pathology’s nomenclature. Indeed, the language used to name and identify a disease has the power to create or intensify social stigma, marginalise subsets of a patient population, and perpetuate health inequalities.
Read MoreMASLD: A New Fatty Liver Disease Nomenclature?

Measuring NAFLD Models of Care: A New Strategic Framework?

Authors: Allen AM, Younossi ZM, Tsochatzis EA et al.
Published in Nature Reviews: Gastroenterology and Hepatology (June 2023)
Models of care (MoCs) establish comprehensive frameworks for the provision of healthcare services along a continuum of care.
Read MoreMeasuring NAFLD Models of Care: A New Strategic Framework?

Dysregulations in Gut Microbiota Composition and Hepatic DNA Methylation in NAFLD: Is There a Link?

Authors: Stols-Gonçalves D, Mak AL, Madsen MS et al.
Published in Gut Microbes (June 2023)
Patients with non-alcoholic fatty liver disease (NAFLD) exhibit alterations in their gut microbiota composition. Indeed, both nuclear and mitochondrial DNA methylation have been linked to the development of NAFLD and metabolic diseases, including obesity and type 2 diabetes mellitus.
Read MoreDysregulations in Gut Microbiota Composition and Hepatic DNA Methylation in NAFLD: Is There a Link?

SUBSCRIBE & FOLLOW US

SUBSCRIBE TO OUR MONTHLY NEWSLETTER TO GET THE LATEST UPDATES